ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2023
Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis.International journal of clinical oncology · 2026Pooled it
- Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Article
- Bridging the Gap Between Research and Policy: Exploring Political Determinants of Immigrant Health in an Urban County With High Cervical Cancer Disparities.Community health equity research & policy · 2026Article
- Towards Cervical Cancer Elimination: Insights from an In-Depth Regional Review of Patients with Cervical Cancer.Current oncology (Toronto, Ont.) · 2026Article
- HPV Genotypes and Survival Outcomes in Invasive Cervical Cancer: A Retrospective Molecular Analysis of FFPE Clinical Samples in an Iranian Cohort.International journal of women's health · 2026Article
- Predictors of survival among cervical cancer patients in Swaziland (Eswatini): A population-based analysis in a resource-limited setting (2016-2024).PLOS global public health · 2026Article
- Global, regional, and national epidemiology of cervical cancer in elderly women from 1990 to 2021 and its prediction to 2035.BMC public health · 2025Article
- Patients with Newly Diagnosed Cervical Cancer Should Be Screened for Anal Human Papillomavirus (HPV) and Anal Dysplasia: Results of Cost and Quality Analysis.Pathogens (Basel, Switzerland) · 2025Article
- Late-stage diagnosis and its impact on survival in Pakistani women with cervical cancer: Findings from an institutional cancer registry.Pakistan journal of medical sciences · 2025Article
- Community-level Social Vulnerability and Cervical Cancer Mortality Among Young and Old Adults in the State of Alabama.Journal of community health · 2025Article
- Sociodemographic inequities in overall survival among younger and older women with cervical cancer.Cancer causes & control : CCC · 2025Article
- miR-29a Downregulates PIK3CA Expression and Inhibits Cervical Cancer Cell Dynamics: A Comparative Clinical Analysis.Current issues in molecular biology · 2024Article
- Trends in cervical cancer: A decade‑long analysis of incidence, survival and demographic disparities in a Northern Italian province.Molecular and clinical oncology · 2024Article
- Accessibility of Criteria to Exit Cervical Cancer Screening at Age 65 Years in the Electronic Health Record.O&G open · 2024Article
- Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors.Gynecologic oncology · 2024Article
- Extended HPV typing test performed better predict value for CIN2+ among elderly women in China.Preventive medicine reports · 2024Article
- Trends in gynecological cancer incidence, mortality, and survival among elderly women: A SEER study.Aging medicine (Milton (N.S.W)) · 2024Article
- Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US.Frontiers in immunology · 2024Article
- Region of origin and cervical cancer stage in multiethnic Hispanic/Latinx patients living in the United States.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThrough adequate screening and follow-up, cervical cancer can be prevented or detected at early-stage (stage I), which is related to excellent survival. Current guidelines recommend discontinuing screening for women ≥65 years with history of normal Pap and/or HPV tests, potentially leaving this age group vulnerable. This study examined late-stage disease in a population-based cohort.
methodsUsing California Cancer Registry data, we identified 12,442 patients ages ≥21 years with a first primary cervical cancer diagnosed during 2009-2018. Proportions of late-stage disease (stages II-IV) and early- and late-stage 5-year relative survival are presented by the age group. Among patients ages ≥65 years, multivariable logistic regression estimated associations of sociodemographic and clinical characteristics with late-stage cervical cancer.
resultsNearly one fifth of patients (n = 2,171, 17.4%) were ≥65 years. More women ages ≥65 years (71%) presented with late-stage disease than younger women (48% in patients ages <65). Late-stage 5-year relative survival was lower for women ≥65 years (23.2%-36.8%) compared with patients <65 (41.5%-51.5%). Characteristics associated with late-stage cervical cancer in women ≥65 years included older age [odds ratio (OR), 1.02; 95% confidence interval (CI), 1.01-1.04; each year], non-adenocarcinoma histologic subtypes, and comorbidities (OR, 1.59; 95% CI, 1.21-2.08).
conclusionsThere remains a significant burden of advanced cervical cancer in women ≥65. IMPACT: Efforts should be made to better understand how the current screening paradigm is failing women of 65 years and older. Future work should focus on determining past screening history, lapses in follow-up care, and non-invasive testing approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.